Hearing loss with kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh

Eur Respir J. 2018 Mar 22;51(3):1701778. doi: 10.1183/13993003.01778-2017. Print 2018 Mar.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aminoglycosides / adverse effects
  • Antitubercular Agents / adverse effects*
  • Bangladesh / epidemiology
  • Body Mass Index
  • Cohort Studies
  • Female
  • Hearing Loss / chemically induced*
  • Humans
  • Kanamycin / adverse effects*
  • Kaplan-Meier Estimate
  • Male
  • Mycobacterium tuberculosis
  • Risk Factors
  • Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

  • Aminoglycosides
  • Antitubercular Agents
  • Kanamycin